Latest News

  • Alkermes to Present Preclinical Data on Novel Selective Effector Cell Activator (SECA™) Immuno-Oncology Candidate at Upcoming American Association for Cancer Research Annual Meeting Read More
  • Alkermes Announces Positive Topline Results from Complete Six-Month Phase 2 Clinical Trial of ALKS 3831 in Schizophrenia Read More
  • Alkermes to Present Data on Aripiprazole Lauroxil and ALKS 3831 at 15th International Congress on Schizophrenia Research Read More

Investors

Learn More

Working at Alkermes

Join Our Team